Home/Filings/4/0001104659-19-006113

4//SEC Filing

Versant Ventures V (Canada), L.P. 4

Accession 0001104659-19-006113

CIK 0001658247other

View on SEC.gov Company Profile

Filed

Feb 5, 7:00 PM ET

Accepted

Feb 6, 5:35 PM ET

Size

29.6 KB

Accession

0001104659-19-006113

Insider Transaction Report

Form 4

Period: 2019-02-04

Crinetics Pharmaceuticals, Inc.CRNX

Versant Ophthalmic Affiliates I, L.P.

10% Owner

Transactions

Other
Common Stock
2019-02-04−9,473→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−14,828→ 84,161 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+9,473→ 9,473 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+678→ 678 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−33,903→ 192,122 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−678→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−445,470→ 2,524,456 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−13,387→ 75,949 total(indirect: See Footnote)

Versant Venture Capital V, L.P.

10% Owner

Transactions

Other
Common Stock
2019-02-04−445,470→ 2,524,456 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−33,903→ 192,122 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+9,473→ 9,473 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−9,473→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+678→ 678 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−678→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−13,387→ 75,949 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−14,828→ 84,161 total(indirect: See Footnote)

Versant Venture Capital V (Canada), LP

10% Owner

Transactions

Other
Common Stock
2019-02-04−13,387→ 75,949 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+678→ 678 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−14,828→ 84,161 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−33,903→ 192,122 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+9,473→ 9,473 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−9,473→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−678→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−445,470→ 2,524,456 total(indirect: See Footnote)

Versant Ventures V, LLC

10% Owner

Transactions

Other
Common Stock
2019-02-04−445,470→ 2,524,456 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−14,828→ 84,161 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−13,387→ 75,949 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−33,903→ 192,122 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−678→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+9,473→ 9,473 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−9,473→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+678→ 678 total(indirect: See Footnote)

Versant Affiliates Fund V, L.P.

10% Owner

Transactions

Other
Common Stock
2019-02-04−445,470→ 2,524,456 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−13,387→ 75,949 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+9,473→ 9,473 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+678→ 678 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−678→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−9,473→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−14,828→ 84,161 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−33,903→ 192,122 total(indirect: See Footnote)

Versant Ventures V (Canada), L.P.

10% Owner

Transactions

Other
Common Stock
2019-02-04−445,470→ 2,524,456 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−13,387→ 75,949 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−14,828→ 84,161 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−33,903→ 192,122 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−9,473→ 0 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+678→ 678 total(indirect: See Footnote)
Other
Common Stock
2019-02-04+9,473→ 9,473 total(indirect: See Footnote)
Other
Common Stock
2019-02-04−678→ 0 total(indirect: See Footnote)

Footnotes (14)

[F1]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V, L.P. ("VVC V") without consideration to its partners.
[F10]The shares are held VV V.
[F11]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members.
[F12]Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN.
[F13]The shares are held VV V CAN.
[F14]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners.
[F2]These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein.
[F3]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Affiliates Fund V, L.P. ("VAF V") without consideration to its partners.
[F4]These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein.
[F5]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") without consideration to its partners.
[F6]These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein.
[F7]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V (Canada) LP ("VVC CAN") without consideration to its partners.
[F8]These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein.
[F9]Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA.

Documents

1 file

4
a4.xmlPrimary
4

Issuer

Crinetics Pharmaceuticals, Inc.

CIK 0001658247

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001716490

Filing Metadata

Form type: 4
Filed: Feb 5, 7:00 PM ET
Accepted: Feb 6, 5:35 PM ET
Size: 29.6 KB

View on SEC.gov